These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1636 related items for PubMed ID: 28864318

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK, Sood NA, Bunz TJ, Coleman CI.
    J Am Heart Assoc; 2018 Apr 13; 7(8):. PubMed ID: 29654196
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 13; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA.
    J Am Heart Assoc; 2016 Jun 13; 5(6):. PubMed ID: 27412905
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH, See LC, Tu HT, Yeh YH, Chang SH, Wu LS, Lee HF, Wang CL, Kuo CF, Kuo CT.
    J Am Heart Assoc; 2018 Apr 05; 7(8):. PubMed ID: 29622587
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH, Skjøth F, Nielsen PB, Kjældgaard JN, Larsen TB.
    JAMA Cardiol; 2017 Aug 01; 2(8):872-881. PubMed ID: 28614582
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB.
    BMJ; 2017 Feb 10; 356():j510. PubMed ID: 28188243
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I, Zhang Y, Saba S.
    Am J Cardiol; 2018 Jul 01; 122(1):69-75. PubMed ID: 29681367
    [Abstract] [Full Text] [Related]

  • 9. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
    Rutherford OW, Jonasson C, Ghanima W, Söderdahl F, Halvorsen S.
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr 01; 6(2):75-85. PubMed ID: 31942972
    [Abstract] [Full Text] [Related]

  • 10. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G, Lip GYH, Holbrook A, Chang Y, Larsen TB, Sun X, Tang J, Mbuagbaw L, Witt DM, Crowther M, Thabane L, Levine MAH.
    Eur J Epidemiol; 2019 Feb 01; 34(2):173-190. PubMed ID: 29948370
    [Abstract] [Full Text] [Related]

  • 11. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L.
    Curr Med Res Opin; 2017 Sep 01; 33(9):1595-1604. PubMed ID: 28635338
    [Abstract] [Full Text] [Related]

  • 12. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
    Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves AB, Yuce H, Lip GYH.
    J Am Geriatr Soc; 2019 Aug 01; 67(8):1662-1671. PubMed ID: 31112292
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
    Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Nadkarni A, Shank TC.
    BMC Cardiovasc Disord; 2019 Jun 13; 19(1):142. PubMed ID: 31195999
    [Abstract] [Full Text] [Related]

  • 14. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY.
    BMJ; 2016 Jun 16; 353():i3189. PubMed ID: 27312796
    [Abstract] [Full Text] [Related]

  • 15. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC, Ahmad A, Petrini M, Tang W, Evans A, Rush T, Thompson D, Oh K, Schwartzman E.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):80-90. PubMed ID: 30500885
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND.
    Chest; 2016 Dec 01; 150(6):1302-1312. PubMed ID: 27938741
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.